Market Trends of Capecitabine Industry
This section covers the major market trends shaping the Capecitabine Market according to our research experts:
Breast Cancer by Indication is Expected to Hold the Largest Market Share in the Global Capecitabine Market
Breast cancer sub-segment is expected to account for the largest share in the market. Dominance can be attributed to the increased prescriptions of the drug as the gold standard due to their proven efficiency in the treatment of breast cancer. Furthermore, their advantages such as increased access, and availability in the form of oral dosage has enhanced convenience to patients. Also, increased prescriptions of capecitabine in combinational therapy along with docetaxel, pertuzumab, and trastuzumab to prolong overall survival in metastatic breast cancer further fuel the growth of the segment during the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall capecitabine market throughout the forecast period. The dominance is due to the rising prevalence of the various types of cancer like colorectal cancer, colon cancer in the region. Growing incidences of cancer can be due to several factors like physical inactivity, obesity, stress, and a sedentary lifestyle. Also, a steep rise in the elderly population due to the presence of baby boomers during the forecast period in the United States results in higher revenue of the region.
For instance, as per the International Diabetes Federation in 2019, about 48 million adults in North America are living with diabetes, among which more than half of the patients are over the age of 65 and are expected to continue in the future. According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.
Thus, a huge target population and increased disposable income in the United States fuels the market. Furthermore, the presence of key players such as Roche, Teva, and others conducting cancer clinical trials are expected to contribute to the significant revenue share in the global capecitabine market.
